J0893 HCPCS code: Injection, decitabine (sun pharma), not therapeutically equivalent to j0894, 1 mg
J0893 is the HCPCS Level II code for injection, decitabine (sun pharma), not therapeutically equivalent to j0894, 1 mg. In 2023 Medicare paid an average of $1.35 per service for J0893 across 3,726 services. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case. In 2023, about 29 clinicians billed Medicare for J0893 for 21 beneficiaries.
Code details
| Field | Value |
|---|---|
| Section | J codes — Drugs administered other than oral method |
| Coverage code | C — Carrier judgment |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | O1E — Other drugs |
| Added | 2023-01-01 |
| Last action effective | 2024-07-01 |
Who bills J0893 (2023)
| Measure | Value |
|---|---|
| Clinicians billing (by place of service) | 29 |
| Medicare beneficiaries | 21 |
| States with claims | 0 |
Counts only. Supplier and clinician names, contact lists and state-by-state detail are in Caduvo.
Medicare utilization for J0893, 2023–2023
| Year | Services | Beneficiaries | Avg. allowed | Avg. paid |
|---|---|---|---|---|
| 2023 | 3,726 | 21 | $1.72 | $1.35 |
What changed for J0893
- 2023-01-01: J0893 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code J0893?
J0893 is the HCPCS Level II code for injection, decitabine (sun pharma), not therapeutically equivalent to j0894, 1 mg. Short descriptor: "Inj, decitabine (sun pharma)".
How much does Medicare pay for J0893?
In 2023, the average Medicare payment was $1.35 per service (average allowed $1.72).
Does Medicare cover J0893?
Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.
Related J08 codes
- J0800 — Injection, corticotropin, up to 40 units
- J0801 — Injection, corticotropin (acthar gel), up to 40 units
- J0802 — Injection, corticotropin (ani), up to 40 units
- J0833 — Injection, cosyntropin, not otherwise specified, 0.25 mg
- J0834 — Injection, cosyntropin, 0.25 mg
- J0840 — Injection, crotalidae polyvalent immune fab (ovine), up to 1 gram
- J0841 — Injection, crotalidae immune f(ab')2 (equine), 120 mg
- J0850 — Injection, cytomegalovirus immune globulin intravenous (human), per vial
- J0870 — Injection, imetelstat, 1 mg
- J0871 — Injection, daptomycin (endo), not therapeutically equivalent to j0878, 1 mg
- J0872 — Injection, daptomycin (xellia), unrefrigerated, not therapeutically equivalent to j0878 or j0873, 1 mg
- J0873 — Injection, daptomycin (xellia), not therapeutically equivalent to j0878 or j0872, 1 mg
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under J0893
- Watch J0893 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for J0893
Compiled by Caduvo from public CMS (Medicare) records, HCPCS release October 2026. Fees are Medicare allowables, not commercial rates. Not reviewed or endorsed by CMS. Not billing or legal advice. Report an error. Data and corrections policy.